Dana-Farber Launches Center for RAS Therapeutics to Target the RAS Oncogene in Cancer
Dana-Farber Cancer Institute will launch the Center for RAS Therapeutics to advance scientific investigation and clinical care for RAS-driven cancers.
Related Articles
New Ancestry-adjusted Lung Cancer Prediction Model
A new ancestry-adjusted risk prediction model, Genomic-informed Care for Motivating High Risk Individuals Eligible for Evidence-based Prevention (GREAT), may aid patients in decision-making around lung…
Tricking cells into trashing cancer
In a study published today in the Journal of Clinical Investigation, Fred Hutch Cancer Center cancer chemical biologist Behnam Nabet and his collaborators describe how…
A phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time magnetic resonance imaging in patients with recurrent high-grade glioma
Journal of Neuro-Oncology – Irinotecan demonstrates anti-tumor efficacy in preclinical glioma models but clinical results are modest due to drug delivery limitations. Convection enhanced delivery…
Lombardi Comprehensive Cancer Center | Washington D.C. DC
Lombardi Comprehensive Cancer Center, Washington D. C. 3,084 likes · 22 talking about this · 4,338 were here. Georgetown Lombardi defeats cancer through scientific discovery…
Victoria’s Secret Global Fund for Women’s Cancers Career Development Awards, in Partnership with Pelotonia & AACR
$206,000 over two years for female assistant professors conducting research with a direct applicability and relevance to the understanding, prevention, interception, early detection, diagnosis, or…
Combos Deemed Safe, Effective in Recurrent Glioblastoma – Oncology Nurse Advisor
Combination treatment with retifanlimab, bevacizumab, and hypofractionated radiotherapy — with or without epacadostat — warrants further investigation, according to researchers.
Clinical Insights: Starting with a Patient Case 1: 74yo 74-Year-Old Patient With NDMM Transplant- Ineligible NDMM
Panelists discuss how to approach treatment decisions for a 74-year-old patient with transplant-ineligible newly diagnosed multiple myeloma patient, considering factors such as age, comorbidities, and…
FDA Issues Guidance Considerations for Tissue Biopsies in Clinical Trials
According to the FDA, biopsies should be optional in clinical protocol when information will be used to evaluate only non-key secondary end points.
Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma
This nonrandomized clinical trial reports outcomes for children with low-risk relapsed Hodgkin lymphoma treated with second-line chemotherapy and involved-field radiotherapy without autologous stem cell transplant.
